CoJourney
Reimagining Cell and Gene Therapy CDMO Services High Purity | High Yield | Rapid Turnaround | Reduced Cost
Reimagining Cell and Gene Therapy CDMO Services High Purity | High Yield | Rapid Turnaround | Reduced Cost
CoJourney is a pioneering CDMO platform for gene therapy that seamlessly integrates plasmid, viral vector, and mRNA generation, analysis, and detection. Founded in 2022, CoJourney operates within the Biopharma, Health Care, and Pharmaceutical industries. The company recently received a significant $30.00M Series A investment on 27 June 2023 from notable investors including Legend Star, Legend Capital, Lake Bleu Capital (Hong Kong) Limited, Hillhouse Ventures, Lenovo Star, Lianrong Zhidao, GL Ventures LLC, and Qingchi Capital. CoJourney's innovative approach and recent investment demonstrate its potential for disrupting the gene therapy sector and creating significant value for investors and the healthcare industry as a whole.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $30.00M | 8 |
-Limited-logo.jpg){kind=logo}
|
27 Jun 2023 |
No recent news or press coverage available for CoJourney.
We care about your data, and we'd love to use cookies make your experience better.